Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points
Authors:
- 13 July 2020
- journal article
- research article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 93 (2) , 128-136
Abstract
Background/Aims: Screening newborns for congenital adrenal hyperplasia (CAH) is problematic owing to the dynamic changes in serum 17-hydroxyprogesterone (17-OHP) levels following birth. Our study objectives were to determine the accuracy of screening, severity of CAH, and biochemical and clinical outcomes of cases detected by our program which collects specimens at 2 time periods following birth. Methods: We reviewed all CAH cases detected in the Northwest Regional Newborn Screening Program from 2003 through 2017. Comparison was made of screening and confirmatory serum 17-OHP, neonatal, maternal, and follow-up auxologic data, steroid treatment doses, and 21-hydroxylase genotype in cases detected on the first versus second test. Results: Out of 164 cases of CAH, 25% were detected on the second screen. Infants detected on the second test had a lower screening 17-OHP (147 vs. 294 ng/mL), lower confirmatory serum 17-OHP (7,772 vs. 14,622 ng/dL), and were more likely to have simple virilizing CAH. There were no identifiable neonatal or maternal factors associated with detection on the second test. 21-Hydroxylase genotypes overlapped in first versus second screen cases. Conclusion: Early collection of specimens necessitated by early discharge resulted in milder CAH cases falling below the screening 17-OHP cutoff. In our program 25% of cases were detected on a routine second screen.Keywords
This publication has 19 references indexed in Scilit:
- Congenital Adrenal Hyperplasia and the Second Newborn ScreenThe Journal of Pediatrics, 2013
- Genotype–phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiencyProceedings of the National Academy of Sciences, 2013
- Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal HyperplasiaPediatrics, 2012
- Cases of Congenital Adrenal Hyperplasia Missed by Newborn Screening in MinnesotaJAMA, 2012
- Molecular analysis of CYP21A2 can optimize the follow‐up of positive results in newborn screening for congenital adrenal hyperplasiaClinical Genetics, 2009
- Use of Steroid Profiling by UPLC-MS/MS as a Second Tier Test in Newborn Screening for Congenital Adrenal Hyperplasia: The Utah ExperiencePediatric Research, 2009
- Congenital Adrenal Hyperplasia due to 21-Hydroxylase DeficiencyEndocrine Reviews, 2000
- Molecular Genotyping in Brazilian Patients with the Classical and Nonclassical Forms of 21-Hydroxylase DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 1998
- Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal HyperplasiaPediatrics, 1998
- Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Journal of Clinical Investigation, 1992